 |
|
|
| |
Rates and predictors of HBsAg loss after discontinuation of effective long-term entecavir or tenofovir therapy in non-cirrhotic
HBeAg-negative chronic hepatitis B patients:
Results from the prospective DARING-B Greek study.
|
| |
| |
Reported by Jules Levin
EASL 2018 April 11-15 Paris France
M Papatheodoridi1, E Rigopoulou2, E Hadziyannis3, K Zachou2, V Xourafas1, A Lyberopoulou2, N Gatselis2, J, S Manolakopoulos1,3, GN Dalekos2,
GV Papatheodoridis1.
|
| |
|
|
|
|
|
